Calithera Biosciences Inc. (NASDAQ:CALA) Relative Strength Index (RSI) is 51.64, with weekly volatility at 6.43% and ATR at 0.14. The CALA stock’s 52-week price range has touched low of $1.87 and a $6.18 high. Intraday shares traded counted 0.62 million, which was 32.39% higher than its 30-day average trading volume of 914.84K. Its shares traded higher over the last trading session, gaining 0.44% on 06/09/21. The shares fell to a low of $2.24 before closing at $2.26. CALA’s previous close was $2.25 while the outstanding shares total 72.25M. The firm has a beta of 1.62.
Investors have identified the Biotechnology company Calithera Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $180.89 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Calithera Biosciences Inc. (CALA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 106.51 million total, with 13.79 million as their total liabilities.
CALA were able to record -22.0 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by -5.96 million. In cash movements, the company had a total of -22.0 million as operating cash flow.
Having a look at the companyâ€™s valuation, the company is expected to record -0.64 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CALA sounds very interesting.
Is the stock of CALA attractive?
In related news, Chief Medical Officer, Orford Keith sold 2,447 shares of the companyâ€™s stock in a transaction that recorded on Dec 16. The sale was performed at an average price of 6.00, for a total value of 14,682. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.